Tag Archives: cancer

Blood Cancer Charity, Anthony Nolan, Selects IGEL Endpoints to Boost Workplace Collaboration and Support Windows 10 Migration

Reading, UK. February 20, 2020 – IGEL, provider of the next-gen edge OS for cloud workspaces, today announced that Anthony Nolan, the pioneering blood cancer charity, has implemented UD3 desktops to support an organizational-wide implementation of Windows 10 and provide rich multimedia capability for over 300 employees. This will boost collaboration and teamwork by enabling… Read More »

Magnetized Particles Show Live Metabolic Activity of Breast Cancer

January 24th, 2020 Medgadget Editors Diagnostics, Materials, Medicine, Oncology, Radiology Current imaging methods that are used to spot tumors don’t provide much information about the rate of activity of the cells making up the diseased tissues. Breast cancer tumors, for example, are mostly classified into a few categories based on hormone receptor and HER2 expression.… Read More »

Researchers urge prostate cancer screening for men with BRCA gene defects

Prostate cancer screening with the prostate-specific antigen (PSA) test has been criticized for flagging too many slow-growing tumors that might never be life-threatening. But some men have inherited gene defects that boost their risk of developing prostate cancers that can be quite aggressive. Is PSA screening particularly well-suited for these genetically defined groups? New research… Read More »

Artificial intelligence identifies previously unknown features associated with cancer recurrence

Artificial intelligence (AI) technology developed by the RIKEN Center for Advanced Intelligence Project (AIP) in Japan has successfully found features in pathology images from human cancer patients, without annotation, that could be understood by human doctors. Further, the AI identified features relevant to cancer prognosis that were not previously noted by pathologists, leading to a… Read More »

FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens

FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens Print this page 20 December 2019 — AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved Enhertu® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult… Read More »